What antiretroviral medications used to treat HIV infection are associated with thrombocytopenia?

HIV Medications Associated with Thrombocytopenia

Based on available evidence, dolutegravir (DTG) is the primary antiretroviral medication with documented case reports of causing severe thrombocytopenia, though this appears to be rare. 1

Specific Antiretroviral Implicated

Dolutegravir (DTG)

• A case report documented severe thrombocytopenia (platelet count ≤50,000/μL) in a patient on DTG-containing antiretroviral therapy 1
• The thrombocytopenia persisted despite controlling HIV and cytomegalovirus infections and stopping valganciclovir (a known bone marrow suppressant)
• Platelet count improved and maintained >100,000/μL after switching from DTG to ritonavir-boosted darunavir 1
• This represents the first reported case of severe DTG-induced thrombocytopenia, suggesting it is an uncommon but documented adverse effect

Important Clinical Context

Zidovudine (AZT) - Historical Consideration

While not mentioned in the provided guidelines, it's worth noting that zidovudine is historically the most well-known antiretroviral causing bone marrow suppression and thrombocytopenia. The guidelines specifically mention that "the majority of antiretroviral agents, excluding zidovudine" correct neutropenia 2, indirectly confirming zidovudine's hematologic toxicity profile.

Other Considerations

• Ritonavir-boosted protease inhibitors (lopinavir, darunavir) have been linked to cardiovascular complications and platelet activation 2, but not specifically to thrombocytopenia
• Abacavir similarly has cardiovascular concerns but no direct thrombocytopenia association in the provided evidence 2

Critical Pitfalls to Avoid

Do not automatically attribute thrombocytopenia to antiretrovirals without considering other causes:

• HIV infection itself causes thrombocytopenia in approximately 40% of patients during their illness 3
• Opportunistic infections (particularly tuberculosis) can cause thrombocytopenia 3
• Coinfections with hepatitis C significantly worsen thrombocytopenia compared to HIV alone 4
• Thrombocytopenia is more prevalent (25.11%) in patients with CD4+ T cells <200 cells/μL 5

Management Algorithm When Thrombocytopenia Develops

1. Confirm persistent thrombocytopenia with repeat testing
2. Evaluate CD4+ count - lower counts (<200 cells/μL) increase likelihood of HIV-related thrombocytopenia 5
3. Screen for opportunistic infections (TB, CMV) and coinfections (HCV) 3, 4
4. Review medication list for other bone marrow suppressants (e.g., valganciclovir, trimethoprim-sulfamethoxazole)
5. If DTG is being used and other causes excluded, consider switching to an alternative regimen such as ritonavir-boosted darunavir or another integrase inhibitor like bictegravir 1
6. Monitor platelet count 1 month after any regimen change 6

The evidence strongly suggests that antiretroviral-induced thrombocytopenia is rare, with DTG being the only agent with published case documentation in the provided literature.